Harke H, Schmidt K, Gretenkort P, Hommerich P, Deutschmann S, Eckes C, Hense W, Kleemann A, Rehorn W, Stöcker H
Institut für Anaesthesie, Städtischen Krankenanstalten Krefeld.
Anaesthesist. 1995 Oct;44(10):687-94. doi: 10.1007/s001010050202.
The safety and tolerance of neuroleptanaesthesia (NLA), balanced anaesthesia (BAL), and intravenous anaesthesia with propofol (IVA) were analysed for the first time in a prospective, randomised clinical trial. METHODS. In all, 1318 surgical patients received either NLA, BAL, or IVA. Patients who had regional anaesthesia, were aged under 18 years, or were non-cooperative or vitally threatened (ASA class i.v. to V) did not participate in the study. Premedication and anaesthetic course were set up at a standard of 30% oxygen and 70% nitrous oxide. Incidents, events, and complications due to anaesthesia were obtained (IEC key of the German Society of Anaesthesia and Critical Care Medicine, DGAI). Furthermore, postanaesthetic alertness based on specific recovery tests and the quality of anaesthesia from the patient's viewpoint, rated by patient questionnaires from the DGAI were evaluated. All parameters were calculated and checked for statistical significance using the chi-square test. RESULTS AND DISCUSSION. The groups were broadly comparable with respect to age (P = 0.91), ASA class (P = 0.42), preoperative blood pressure (P = 0.36), and length of anaesthesia (P = 0.82). The anaesthesia, which averaged 103 min, comprised the following regimens: (1) NLA: 7.1 mg droperidol and 0.008 mg/kg body weight fentanyl, (2) IVA: 493.4 mg propofol and 0.004 mg/kg body weight fentanyl, and (3) BAL: 2.6 mg droperidol and 0.004 mg/kg body weight fentanyl with 0.4 vol.% isoflurane. With respect to anaesthetic risk, the following reactions were observed: the use of NLA led to a high incidence of tachycardia (P = 0.001), arrhythmias (P = 0.05), and hypertensive reactions (P = 0.001), whereas in the IVA group only hypotension (P = 0.0001) occurred. However, after the use of BAL none of the aforementioned complications were detectable to any considerable degree. Similarly, patients who had cardiac disease showed greater IEC changes after the use of NLA than after BAL or IVA (P = 0.02) (Tables 1 and 2). The heart rates and blood pressures during BAL and IVA were extremely stable, and therefore, vasoactive therapy was required considerably less in comparison to NLA (P = 0.001) (Table 4). Recovery after the use of IVA was strikingly rapid: the patient's responsiveness, orientation, and ability to concentrate was significantly better than after the other anaesthetic regimen (P = 0.01) (Table 5). With regard to the typical discomforts after anaesthesia, IVA was highly superior to BAL and NLA: nausea (P = 0.0003) and retching (P = 0.03) hardly ever occurred (Table 6). Due to the tolerable manner of waking up and rapid return of orientation and the ability to concentrate, IVA was highly favoured by the patients (P = < 0.01) (Table 7). CONCLUSION. The present results show clear clinical advantages of BAL and IVA in contrast to neuroleptanaesthesia. Due to the very low incidence of side effects such as nausea and vomiting IVA was highly recommended by the patients, at least in part because of the rapid recovery time.
在一项前瞻性随机临床试验中,首次对神经安定麻醉(NLA)、平衡麻醉(BAL)和丙泊酚静脉麻醉(IVA)的安全性和耐受性进行了分析。方法:总共1318例手术患者接受了NLA、BAL或IVA麻醉。接受区域麻醉、年龄在18岁以下、不合作或有生命危险(ASA分级IV级至V级)的患者未参与本研究。术前用药和麻醉过程设定为标准的30%氧气和70%氧化亚氮。记录麻醉相关的事件、情况和并发症(德国麻醉与重症医学学会的IEC关键指标,DGAI)。此外,基于特定恢复测试评估麻醉后警觉性,并根据DGAI的患者问卷从患者角度评估麻醉质量。所有参数使用卡方检验进行计算并检查统计学意义。结果与讨论:各组在年龄(P = 0.91)、ASA分级(P = 0.42)、术前血压(P = 0.36)和麻醉时长(P = 0.82)方面大致可比。平均时长为103分钟的麻醉包括以下方案:(1)NLA:7.1毫克氟哌利多和0.008毫克/千克体重芬太尼;(2)IVA:493.4毫克丙泊酚和0.004毫克/千克体重芬太尼;(3)BAL:2.6毫克氟哌利多和0.004毫克/千克体重芬太尼加0.4%体积分数异氟烷。关于麻醉风险,观察到以下反应:使用NLA导致心动过速(P = 0.001)、心律失常(P = 0.05)和高血压反应(P = 0.001)的发生率较高,而在IVA组仅发生低血压(P = 0.0001)。然而,使用BAL后,上述并发症均未达到任何显著程度。同样,患有心脏病的患者在使用NLA后比使用BAL或IVA后显示出更大的IEC变化(P = 0.02)(表1和表2)。BAL和IVA期间的心率和血压极其稳定,因此,与NLA相比,血管活性药物治疗的需求显著减少(P = 0.001)(表4)。使用IVA后的恢复非常迅速:患者的反应性、定向能力和注意力明显优于其他麻醉方案(P = 0.01)(表5)。关于麻醉后典型的不适,IVA远优于BAL和NLA:恶心(P = 0.0003)和干呕(P = 0.03)几乎从未发生(表6)。由于苏醒方式可耐受且定向能力和注意力迅速恢复,IVA受到患者的高度青睐(P = < 0.01)(表7)。结论:目前的结果表明,与神经安定麻醉相比,BAL和IVA具有明显的临床优势。由于恶心和呕吐等副作用发生率极低,患者高度推荐IVA,至少部分原因是恢复时间快。